IRB #

STUDY00019537

Title

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Principal Investigator

Eric Anderson

Study Purpose

This research is being done to find out if the medication called durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy.

Medical Condition(s)

Non Small Cell Lung Cancer stage I/II

Eligibility Criteria

Stage I to II Non Small Cell Lung Caner, and planned to receive definitive treatment with SBRT (Stereotactic Body Radiation Therapy)

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Patients will receive their assigned treatment for up to 24 months and follow up for up to 72 months.

Minors Included

No

Contact

OHSU Knight Cancer Institute
503-494-1080
trials@ohsu.edu

Sponsor

Astrazeneca AB

Recruitment End

09/20/2020

Compensation Provided

No


Go Back